Validity of administrative database detection of previously resolved hepatitis B virus in Japan.
Aged
Algorithms
Arthritis, Rheumatoid
/ complications
Biostatistics
/ methods
Databases, Factual
Female
Hepatitis B
/ diagnosis
Hepatitis B virus
/ isolation & purification
Humans
Immunosuppression Therapy
/ adverse effects
Immunosuppressive Agents
/ therapeutic use
Incidence
Japan
Male
Middle Aged
Predictive Value of Tests
Reproducibility of Results
Retrospective Studies
Virus Activation
biostatistics and bioinformatics
chemotherapy
disease control
hepatitis B virus
infection
reactivation
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
25
02
2019
accepted:
03
07
2019
pubmed:
10
7
2019
medline:
9
7
2020
entrez:
9
7
2019
Statut:
ppublish
Résumé
The risk of hepatitis B virus (HBV) reactivation has increased owing to advances in the immunosuppressive therapy field. However, the HBV reactivation incidence among patients with previously resolved HBV (prHBV) infection during immunosuppressive therapy for rheumatoid arthritis (RA) remains unclear. The objective of this work is to describe the validity of detecting prHBV infection from administrative data through comparisons with chart abstraction and determine the incidence of HBV reactivation during immunosuppressive therapy for RA in Japan. In this retrospective cohort study, data on selected patients were extracted from administrative claims data. To identify patients with prHBV infection and de novo hepatitis, and HBsAg carriers, we conducted chart abstraction. The incidence rate of de novo hepatitis was 1.23 of 100 person-years. The positive predictive value (PPV) and its 95% confidence interval (CI) of administrative data for the identification of suspected prHBV infections was 85.8% (95% CI: 81.7%-89.3%). This study evaluated the PPV of the algorithm of HBV-DNA testing with immunosuppressive therapy performed four times or more per year for the detection of prHBV infection from administrative data. Additionally, we determined the incidence rate of HBV reactivation among preHBV infections during immunosuppressive therapy for RA to be 1.23 of 100 person-years.
Identifiants
pubmed: 31283012
doi: 10.1002/jmv.25540
pmc: PMC6771469
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1944-1948Informations de copyright
© 2019 The Authors. Journal of Medical Virology Published by Wiley Periodicals, Inc.
Références
Int J Cardiol. 2015 Dec 15;201:96-101
pubmed: 26292275
Ann Rheum Dis. 2017 Jun;76(6):1051-1056
pubmed: 27934678
J Epidemiol. 2017 Oct;27(10):476-482
pubmed: 28142051
Hepatol Res. 2013 Feb;43(2):97-105
pubmed: 23409848
J Med Virol. 2019 Nov;91(11):1944-1948
pubmed: 31283012
J Viral Hepat. 2018 Nov;25(11):1312-1320
pubmed: 29770539
Hepatol Res. 2012 Jul;42(7):627-36
pubmed: 22686858
J Gastroenterol. 2016 Oct;51(10):999-1010
pubmed: 26831356
Hepatol Res. 2014 Jan;44 Suppl S1:1-58
pubmed: 24397839
Clin Epidemiol. 2016 May 31;8:133-40
pubmed: 27330328
Diabetes Care. 2002 Mar;25(3):512-6
pubmed: 11874939